Welcome to our dedicated page for Helix Biopharma news (Ticker: HBPCF), a resource for investors and traders seeking the latest updates and insights on Helix Biopharma stock.
Helix BioPharma Corp. reports developments as a clinical-stage oncology and immuno-oncology company built around its proprietary DOS47 technology platform. Company updates focus on cancer-therapy development, including its primary therapeutic candidate L-DOS47, as well as investor presentations that describe the direction of its oncology programs.
Recurring news also covers corporate governance and public-company administration, including board and management appointments, auditor changes, warrant-related capital actions, and updates involving corporate assets and subsidiaries. The company’s securities have been referenced on the Toronto Stock Exchange, OTC market, and Frankfurt market.
Helix BioPharma (OTC:HBPCF), a clinical-stage oncology company, will present at the Q3 2025 Investor Summit Virtual on September 16, 2025. The company's CEO, Dr. Thomas Mehrling, will showcase their upcoming Phase Ib/Randomized Phase II clinical study of L-DOS47 combined with pembrolizumab for first-line treatment of non-small cell lung cancer (NSCLC).
Additionally, Helix will discuss their planned NASDAQ uplisting in Q1 2026. The presentation aims to highlight the company's strategy in developing oncology assets and expanding their market presence. Investors will have opportunities for one-on-one meetings with the CEO during the two-day virtual event.
Helix BioPharma Corp. announced the appointment of Artur Gabor as the new Chief Executive Officer and added three new members to its Board of Directors aimed at enhancing corporate governance and growth capabilities. The new board members include Jerzy Leszczyński, Christopher Maciejewski, and Jacek Antas, each bringing significant experience in their respective fields. This leadership change is expected to bolster the company's strategic direction in immuno-oncology therapies based on the proprietary DOS47 platform.
Helix BioPharma Corp. announced the resignation of Heman Chao as CEO and CSO, effective September 1, 2021. Chao, who joined in 2008, will transition to Chair of the Scientific Advisory Board. The Board appreciates his dedication to advancing immunotherapy research and will seek candidates for the new CEO. The company remains focused on its clinical programs, particularly the primary drug candidate L-DOS47, which is expected to drive future growth. The Board expresses confidence in the current management team.
Helix BioPharma Corp. announced the appointment of Marcum LLP as its new auditor, replacing BDO Canada LLP. A Notice of Change of Auditor has been filed under the company's SEDAR profile. Additionally, the company received conditional approval from the Toronto Stock Exchange to extend the exercise period of 4,830,175 common share purchase warrants for two years. These warrants represent approximately 3.4% of the company’s outstanding shares and were originally issued during private placements between July 2014 and August 2016.
Helix BioPharma Corp. has updated its progress on the divestiture of its remaining shares in Polish subsidiary Helix Immuno-Oncology S.A. The company accepted an offer from CAIAC Fund Management AG for gross proceeds of PLN6,700,000 (~CAD2,300,000). Due to COVID-19-related delays, the transaction's closing date has been extended to October 30, 2020, pending approval from the Financial Market Authority in Liechtenstein and a minimum capital raise of PLN7,300,000 by the fund.